Showing 1751-1760 of 1922 results for "".
- Teva, Drugmakers in Talks With U.S. to End Generics Probeshttps://modernod.com/news/teva-drugmakers-in-talks-with-u-s-to-end-generics-probes/2477123/Teva Pharmaceutical Industries and other generic drugmakers have held talks with the U.S. Justice Department in the past 6 months about resolving a long-running criminal antitrust probe of alleged price-fixing by the companies, according to people familiar with the matter, as
- Report: Novartis Weighing Takeover Offer for The Medicines Companyhttps://modernod.com/news/report-novartis-weighing-takeover-offer-for-the-medicines-company/2477107/Novartis is considering making an offer to acquire The Medicines Company and is currently conducting due diligence on the drugmaker, Bloomberg reported Tuesday, citing people close to the matter. The sources suggested that The Medicines Company, which has a market value of about $4.7 bi
- Phase 3 Study Shows Teprotumumab Significantly Reduced Double Vision for People with Active Thyroid Eye Diseasehttps://modernod.com/news/new-data-from-teprotumumab-phase-3-study-shows-significantly-reduced-double-vision-for-people-with-active-thyroid-eye-disease/2476988/Horizon Therapeutics announced new data from the phase 3 OPTIC confirmatory clinical trial showing that teprotumumab provided significant benefit on several effects of active thyroid eye disease (TED) compared with placebo, including diplopia (double vision), quality of life (QoL) and clinical ac
- On World Sight Day, Allergan Launches National Campaign to Raise Awareness of Glaucomahttps://modernod.com/news/on-world-sight-day-allergan-launches-national-campaign-to-raise-awareness-of-glaucoma/2476984/Allergan announced a national education campaign called “My Glaucoma.” The campaign is designed to help people understand the burden of living with glaucoma and empower those with the disease and their caregivers to feel comfortable speaking with their doctor about a treatment
- Phase 2 Study Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to AMDhttps://modernod.com/news/phase-2-study-highlights-efficacy-and-safety-data-of-intravitreal-apl-2-for-geographic-atrophy-secondary-to-amd/2476891/Apellis Pharmaceuticals announced details about its phase 2 FILLY study investigating intravitreal (IVT) APL-2 (pegcetacoplan) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) have been published in Ophth
- Bausch Health CEO: Big Pharma Will Survive US Drug Regulationshttps://modernod.com/news/bausch-health-ceo-big-pharma-will-survive-us-drug-regulations/2476798/Bausch Health Chariman and CEO Joseph C. Papa told CNBC on Wednesday that he isn’t too concerned about the future of the pharmaceutical industry despite pledges from Congress to lower
- Alcon Launches New Website to Educate Patients on LASIK and Contoura Visionhttps://modernod.com/news/alcon-launches-new-website-to-educate-patients-on-lasik-and-contoura-vision/2476758/Alcon has launched a new website, yourlasiksolution.com, to help educate patients about LASIK and surgery options, including its WaveLight LASIK technology with Contoura Vision. Alcon gathered input from real-world LASIK patients about the type of information that was critical to make an informed
- New Age-Related Macular Degeneration Common in Untreated Fellow Eyeshttps://modernod.com/news/new-age-related-macular-degeneration-common-in-untreated-fellow-eyes/2476748/New age-related macular degeneration (AMD) develops in about a quarter of fellow eyes to those treated for neovascular AMD with intravitreal anti-VEGF agents, according to a post hoc analysis of the VIEW 1 and VIEW 2 studies, as reported b
- Alimera Sciences Announces Launch of Direct-to-Patient Marketing Campaign for Iluvienhttps://modernod.com/news/alimera-sciences-announces-launch-of-direct-to-patient-marketing-campaign-for-iluvien/2476603/Alimera Sciences announced the launch of a direct-to-patient (DTP) marketing campaign intended to raise awareness and educate patients diagnosed with diabetic macular edema (DME) and their caregivers about the therapeutic and dosing benefits of Iluvien. The campaign will be supported by the websi
- Biotech Healthcare Announces Korean Good and Manufacturing Practices Approvalhttps://modernod.com/news/biotech-healthcare-announces-korean-good-and-manufacturing-practices-approval/2476544/Biotech Healthcare has received KGMP (Korean Goods & Manufacturing Practice) approval, allowing its ophthalmic products to be accessible to South Korean markets. “Today when we talk about addressing the urgent need of global eye care problems, may that be cataracts or the myopic wave t